Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7327622 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2023504 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2023499 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL7327626 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13109503 | 0.89 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL24411297 | 0.87 | EPHX1 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5560650 | 0.87 | EPHX1 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2954122 | 0.87 | EPHX1 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29819835 | 0.87 | EPHX1 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL22980251 | 0.87 | CHRM2 (0.35) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-6992102-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | HAMANN LAWRENCE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | HSD17B10 106/4885CHRM2 636/4885CHRM1 611/4885 |
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | HSD17B10 4218/4885CHRM2 4448/4885CHRM1 4405/4885 |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | HSD17B10 106/4885CHRM2 636/4885CHRM1 611/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | HSD17B10 4192/4885CHRM2 4660/4885CHRM1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.